



Therapeutic Target Developments in Pancreatic Cancer

Guest Editors:

Prof. Dr. Guishan Xiao

Molecular Pharmacology at
School of Chemical Engineering,
Dalian University of Technology,
Dalian, China

Dr. Bin Lu

Department of Cell Biology and
Genetics, School of Basic Medical
Sciences, Hengyang Medical
School, University of South
China, Hengyang, China

Deadline for manuscript
submissions:

closed (12 May 2024)

Message from the Guest Editors

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer death in the Western world. The prognosis is poor, with 1- and 5-year survival rates of about 20% and 6%, respectively. Systemic chemotherapy administered either after tumor resection surgery or in patients with metastatic disease has been shown to prolong survival; however, surgery is the only curative treatment. About 20% of patients with pancreatic cancer can be operated on with curative intent, because most have locally advanced or metastatic pancreatic cancer at the time of diagnosis. Resistance to therapy resulting from the unique tumor environment of PDAC, consisting of desmoplastic stroma, immune suppressive cells, and activated fibroblasts, as well as a lack of biomarkers, remains a clinical challenge, one that is unmet in terms of the development of novel therapeutic targets for an effective administration of the disease. In this Special Issue, we would like to solicit manuscripts covering the development of novel therapeutical drug targets and their associated mechanisms, which can provide a basis for exploring new targets and developing more advanced strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com